ProCE Banner Activity

TRANSCEND NHL 001: Patient-Reported Outcomes With Liso-Cel in Patients With Relapsed/Refractory Aggressive B-Cell NHL

Slideset Download
Conference Coverage

Patients with relapsed/refractory B-cell NHL who showed clinical response to liso-cel reported greater quality-of-life improvement vs nonresponders.

Released: December 17, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company